Oppenheimer upgraded Aldeyra to Outperform from Perform with a $10 price target. Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>> See today’s best-performing stocks on TipRanks >> Read More on ALDX: Aldeyra in FDA clinical plan for NDA resubmission of reproxalap for DED Aldeyra Therapeutics Unveils Reproxalap Development Update Aldeyra files $200M mixed securities shelf Is ALDX a Buy, Before Earnings? Biotech Alert: Searches spiking for these stocks today Disclaimer & DisclosureReport an Issue
